Thursday, October 1, 2020

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

Home

Registration

Patient Tools

Please protect the confidentiality of your patients by not revealing or sharing login credentials.

Forgot User Name

Forgot Password

Change Password

To register for online services, click here:

Already registered?
Log in above
Or call 1-877-336-3736

PRESCRIBING INFORMATION

PROVENGE^® (sipuleucel-T)

CONTACT US

Phone Numbers
Voice:	1-877-336-3736
Fax:	1-877-556-3737

Hours: Monday through Friday
8:00 AM-9:00 PM ET

You are about to leave Dendreon ON Call

You are now leaving <a href="http://www.enrollment.dendreononcall.com">www.enrollment.dendreononcall.com</a>

Warning, you are being directed to another website.

Close Continue to www.dendreon.com

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

PROVENGE^® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence = 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

P-A-04.12-087.00